



## Vaccines Based on Dendritic Cells: Breaking Barriers to New Immune Response Approach

Guest Editor:

**Prof. Dr. Soledad Lopez-Enriquez**

Department of Medical Biochemistry, Molecular Biology, Immunology School of Medicine, Universidad de Sevilla, Av. Sanchez Pizjuan s/n, 41009 Seville, Spain

Deadline for manuscript submissions:

**20 February 2025**

### Message from the Guest Editor

Dendritic cells (DCs) are versatile cells that bridge the gap between innate and adaptive immune responses. They are potent antigen-presenting cells that control both T cell immunity and tolerance. DCs are often downregulated in diseases such as cancer, where they are called tolerogenic DCs and have a crucial role in inducing peripheral tolerance. Recent studies on vaccines based on nucleic acids such as DNA or mRNA have shown remarkable results in treating diseases such as COVID-19 and multiple solid tumors. We invite contributions of original reports, observations, or reviews to highlight (i) their role in preventing relapses in cancer, (ii) the metabolic signaling pathway target, (iii) the ability to cross the blood–brain barrier in pathological processes or as a vaccination strategy, and (iv) recent advances in novel therapeutic vaccines based on dendritic cells.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)